Drug Drug Interaction Study Of Crizotinib With Esomeprazole.

Phase 1 Completed 16 enrolled Pfizer

NaSingle-groupOpen-labelBasic science

Summary

This is an open-label, randomized, cross-over, single dose study in healthy volunteers to evaluate the potential effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of crizotinib. Each subject enrolled will receive two single oral doses of crioztinib with or without esomeprazole separated by a washout period of at least 14 days.

Timeline

Start: 2012-05
Primary completion: 2012-05
Completion: 2012-05

Publications

Xu H, O'Gorman M, Matschke K, Boutros T, Brega N, Tan W, Bello A. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants. Clin Pharmacol Drug Dev. 2022 Jan;11(1):34-42. doi: 10.1002/cpdd.1032. Epub 2021 Nov 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Crizotinib	Small molecule	250 mg	Oral
Subject	Esomeprazole	Small molecule	40 mg	—

Indications

No indication recorded.